Atossa Therapeutics Inc (ATOS)

10:22 AM

Atossa Therapeutics, Inc. Appoints Mark Daniel as Chief Financial Officer - MarketScreener

10:22 AM

08:46 AM

Atossa appoints Mark Daniel as CFO to prepare for commercial operations By Investing.com - Investing.com South Africa

08:46 AM

08:23 AM

Atossa Therapeutics Appoints New Chief Financial Officer - TipRanks

08:23 AM

08:00 AM

Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness - PR Newswire

08:00 AM

07:53 AM

Atossa Therapeuticsappoints Mark Daniel as CFOSEC filing - MarketScreener

07:53 AM

05:31 AM

What MACD and RSI say about Atossa Therapeutics Inc.CEO Change & Growth Oriented Trading Recommendations - newser.com

05:31 AM

04:28 AM

Can Atossa Therapeutics Inc. stock sustain market leadershipQuarterly Risk Review & Safe Capital Growth Stock Tips - newser.com

04:28 AM

03:49 AM

Intraday pattern recognizer results for Atossa Therapeutics Inc.Insider Buying & Real-Time Market Trend Scan - newser.com

03:49 AM

03:15 AM

What moving averages say about Atossa Therapeutics Inc.July 2025 Spike Watch & Daily Market Momentum Tracking - newser.com

03:15 AM

Oct 13, 2025

Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals - StreetInsider

Oct 13, 2025

Oct 13, 2025

How Atossa Therapeutics Inc. stock trades before earnings2025 Support & Resistance & Fast Gain Swing Alerts - newser.com

Oct 13, 2025

Oct 13, 2025

Will Atossa Therapeutics Inc. stock split again soonMarket Activity Report & Reliable Volume Spike Alerts - newser.com

Oct 13, 2025

Oct 13, 2025

Applying big data sentiment scoring on Atossa Therapeutics Inc.Gold Moves & AI Driven Stock Movement Reports - newser.com

Oct 13, 2025

Oct 13, 2025

Will Atossa Therapeutics Inc. stock benefit from commodity pricesJuly 2025 Macro Moves & Free Technical Pattern Based Buy Signals - newser.com

Oct 13, 2025

Oct 13, 2025

Published on: 2025-10-13 08:27:23 - newser.com

Oct 13, 2025

Oct 13, 2025

Atossa Therapeutics (ATOS) Strengthens Patent Portfolio for Z-en - GuruFocus

Oct 13, 2025

Oct 13, 2025

Israeli patent No. 304863 for Z-endoxifen — Atossa secures enteric 90% purity, dose & manufacturing claims - Stock Titan

Oct 13, 2025

Oct 13, 2025

Can Atossa Therapeutics Inc. (YAG2) stock stage a strong rebound this quarterChart Signals & Safe Entry Point Alerts - newser.com

Oct 13, 2025

Oct 13, 2025

Regression analysis insights on Atossa Therapeutics Inc. performancePortfolio Gains Summary & High Accuracy Trade Signal Alerts - newser.com

Oct 13, 2025

Oct 11, 2025

Can a trend reversal in Atossa Therapeutics Inc. lead to recoveryEarnings Growth Report & Stepwise Swing Trade Plans - newser.com

Oct 11, 2025

Oct 11, 2025

NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Newport Daily News

Oct 11, 2025

Oct 10, 2025

Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Pueblo Chieftain

Oct 10, 2025

Oct 10, 2025

Is Atossa Therapeutics Inc. stock ready for a breakoutJuly 2025 Sector Moves & Breakout Confirmation Alerts - newser.com

Oct 10, 2025

Oct 10, 2025

How to forecast Atossa Therapeutics Inc. trends using time seriesGap Down & Weekly Market Pulse Updates - newser.com

Oct 10, 2025

Oct 10, 2025

Is Atossa Therapeutics Inc. stock entering bullish territoryMarket Growth Report & Fast Moving Stock Trade Plans - newser.com

Oct 10, 2025

Oct 10, 2025

Comparing Atossa Therapeutics Inc. in custom built stock radars2025 Earnings Surprises & Stepwise Entry and Exit Trade Signals - newser.com

Oct 10, 2025

Oct 10, 2025

Published on: 2025-10-10 02:05:17 - newser.com

Oct 10, 2025

Oct 09, 2025

Weiss Ratings Reiterates "Sell (D-)" Rating for Atossa Genetics (NASDAQ:ATOS) - MarketBeat

Oct 09, 2025

Oct 09, 2025

Can Atossa Therapeutics Inc. (YAG2) stock deliver double digit returnsOptions Play & Weekly Breakout Watchlists - newser.com

Oct 09, 2025

Oct 09, 2025

Signal strength of Atossa Therapeutics Inc. stock in tech scannersTrade Entry Report & Weekly Momentum Picks - newser.com

Oct 09, 2025

Oct 09, 2025

Can Atossa Therapeutics Inc. (YAG2) stock reach $200 price targetQuarterly Trade Report & Low Volatility Stock Recommendations - newser.com

Oct 09, 2025

Oct 07, 2025

Atossa Therapeutics (ATOS) Announces Upcoming Virtual Meeting - GuruFocus

Oct 07, 2025

Oct 06, 2025

Atossa streamlines breast cancer trial to focus on 2026 NDA plans - Investing.com

Oct 06, 2025

Oct 06, 2025

Atossa Therapeutics streamlines Evangeline breast cancer clinical trial to prioritize for 2026 NDA-enabling activities - MarketScreener

Oct 06, 2025

Oct 06, 2025

Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities - PR Newswire

Oct 06, 2025

Oct 06, 2025

Atossa Therapeutics Inc. stock retracement – recovery analysisEarnings Growth Report & Free Fast Gain Swing Trade Alerts - newser.com

Oct 06, 2025

Oct 06, 2025

Can Atossa Therapeutics Inc. stock hit analyst price targetsWeekly Risk Report & Consistent Income Trade Recommendations - newser.com

Oct 06, 2025

Oct 02, 2025

Atossa Therapeutics appoints Janet Rea as SVP of R&D By Investing.com - Investing.com Nigeria

Oct 02, 2025

Oct 01, 2025

Atossa Therapeutics appoints Janet Rea as SVP of R&D - Investing.com

Oct 01, 2025

Oct 01, 2025

What drives Atossa Therapeutics Inc YAG2 stock priceDouble Top/Bottom Patterns & Superior Trading Ideas - earlytimes.in

Oct 01, 2025

Oct 01, 2025

Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones - StreetInsider

Oct 01, 2025

Oct 01, 2025

Veteran Drug Approval Expert Returns to Atossa Therapeutics to Advance Breakthrough Breast Cancer Treatment - Stock Titan

Oct 01, 2025